TinyGemsBreaks Archive - Page 105 of 125

WednesdaySep 21, 2022 3:05 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Collaborates to Bridge Concept-to-Deployment Gap in Autonomous Driving Technology

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, has announced its collaboration with NVIDIA to add Cepton lidar models into NVIDIA DRIVE Sim(TM). According to the update, DRIVE Sim is an end-to-end simulation platform that enables large-scale, physically based multi-sensor simulation to support the development and validation of autonomous driving. “Lidar is essential to autonomous mobility, but deploying lidar at scale entails extensive testing and validation, sometimes in scenarios difficult to access in real life,” said Dr. Jun Pei, Cepton’s co-founder and CEO. “Simulation plays a significant role in bridging the gap between concept and…

WednesdaySep 21, 2022 1:07 pm

TinyGemsBreaks — Mullen Automotive Inc.’s (NASDAQ: MULN) Bollinger Motors Teams Up with Wabash to Develop New Body on Electric Chassis

Mullen Automotive (NASDAQ: MULN), through its recent majority acquisition, Bollinger Motors Inc., is partnering with Wabash, a leading truck body and trailer manufacturer. The partnership will focus on developing a stronger, lighter, refrigerated truck body on an electric chassis. The plan is to seamlessly integrate Bollinger’s Class 4 electric chassis cab with Wabash’s lightweight composite technology, EcoNex(TM), which will be used in truck bodies and trailers. According to the announcement, the exclusive EcoNex technology’s composite material is lighter and more durable and thermally efficient than other commercial products. With that in mind, the new offering will feature weight savings because…

WednesdaySep 21, 2022 12:10 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming Scientific and Investor Conferences

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced its participation in upcoming conferences taking place in September and October 2022. The company’s CEO Doug Drysdale participated in a panel discussion titled “Trials to Treatments” at the Interdisciplinary Conference on Psychedelic Research, Psychedelic Science, Ethics & Business Event in Haarlem, Amsterdam. The announcement includes further details on additional conferences and the participation schedule for Drysdale and additional members of Cybin’s management team in panel discussions and presentations. The additional events include the Interdisciplinary Conference on Psychedelic Research, Sept. 22-24,…

WednesdaySep 21, 2022 11:36 am

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on Recently Announced $20M Public Offering

Aditxt Inc. (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has closed on its recent public offering. The offering was comprised of 3,333,333 shares of common stock or common stock equivalents; the offering also included warrants to purchase up to 3,333,333 shares of common stock. The combined offering price to the public was $6 per share and associated warrant, with the warrants, which are exercisable upon being issued, having an exercise price of $6 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering, which resulted…

WednesdaySep 21, 2022 11:26 am

TinyGemsBreaks – Knightscope Inc. (NASDAQ: KSCP) to Take the Spotlight with a Robot Show in Sterling, Virginia

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, has announced that its Robot Roadshow will land at 22895 Ladbrook Drive in Sterling, Virginia, on Sept. 20-21, 2022. The Robot Roadshow is an engaging experiential event designed to grab attention, forge direct connections with potential clients, and strike up conversations in a compelling fashion. The announcement reads, “The Robot Roadshow has made 56 landings in 22 states and Washington, D.C., to date. Knightscope’s crime-fighting robots tour the U.S. in a space-age, NASA-like ‘pod’ allowing attendees to experience all the technology that is enabling…

TuesdaySep 20, 2022 2:26 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Hypertension Drug Market with Proprietary Drug-Delivery Method

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is focused on establishing a stronghold in the $28 billion hypertension drug market. The company’s exclusive therapeutic, DehydraTECH-CBD, has shown exciting potential as an alternative to traditional cannabidiol (“CBD”) dosing methods; the proprietary treatment may offer improved and more rapid absorption of drugs into the bloodstream and brain. According to the announcement, only one FDA-approved CBD drug is currently available on the market; that drug is for pediatric epilepsy. Lexaria is working to offer the second-ever, FDA-approved CBD therapeutic, designed to treat hypertension. The market for the treatment is tremendous,…

TuesdaySep 20, 2022 1:42 pm

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces R&B Milestones, Beats Anticipated Timeframe

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has successfully reached key research and development (“R&D”) milestones that were identified in the company’s acquisition agreement of Adelia Therapeutics in 2020. The milestones were reached faster than expected, and have helped Cybin make progress on its path toward clinical drug development. The milestones were key in moving Cybin’s psychedelic programs from lab to clinic and have enabled the company to discover potential new drug formulations and delivery methods as well as create clinical protocols for psychedelic compounds and support clinical-stage development of CYBN’s proprietary CYB003…

TuesdaySep 20, 2022 10:38 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Release FY 2022 Financial Report, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, will be releasing its financial report for fiscal year 2022, the period ended June 30, 2022, later this month. The company has announced that it will release the financial report, along with business highlights, on Sept. 23, 2022. In addition, the company has announced a conference call and webcast to be held the same day at 1 p.m. ET. Those interested in listening in on the conference call can register for the call; they will then receive information about how to dial in to the…

FridaySep 16, 2022 2:10 pm

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Pricing of Public Offering

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has released the pricing of its public offering. The offering consists of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof) along with warrants to purchase up to 3,333,333 additional shares of its common stock. According to the announcement, the combined offering price will be $6 per share (or common stock equivalent) and associated warrants. The company noted that in addition to the $6 per share exercise price, the warrants will be immediately exercisable with an…

FridaySep 16, 2022 1:45 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leading Charge to Find Potential Treatment Option for GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company, is looking to fill a gap in the treatment of Glioblastoma Multiforme (“GBM”), an aggressive form of cancer that occurs in the brain or spinal cord, with its lead product candidate Berubicin. “GBM is considered one of the most complex, deadly and treatment-resistant cancers. And although it is regarded as rare, between 12,000 and 15,000 Americans are diagnosed with the condition every year. Even more devastatingly, the National Brain Tumor Society (‘NBTS’) estimates that over 10,000 individuals with GBM succumb to the disease annually. GBM has a five-year survival rate of…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks